BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...created position, and Michael Detke as CMO. Detke, who succeeds Samer Kaba, was CMO of Embera NeuroTherapeutics Inc....
BioCentury | Aug 15, 2016
Company News

Embera, NIH neurology news

...on Drug Abuse (NIDA) to develop metyrapone/oxazepam ( EMB-001 ) to treat cocaine use disorder. Embera...
...plans to advance the product through a Phase II proof-of-concept trial with the NIDA support. Embera NeuroTherapeutics Inc....
BioCentury | Jan 25, 2016
Clinical News

Metyrapone/oxazepam: Phase I data

...metyrapone/24 mg oxazepam. After 24 hours, subjects received twice-daily doses of EMB-001 for 7 days. Embera NeuroTherapeutics Inc....
BioCentury | Jun 15, 2015
Clinical News

Metyrapone/oxazepam: Phase I started

...metyrapone/24 mg oxazepam. After 24 hours, subjects will then receive twice-daily doses for 7 days. Embera NeuroTherapeutics Inc....
BioCentury | Apr 13, 2015
Financial News

Embera completes venture financing

Embera NeuroTherapeutics Inc. , Shreveport, La. Business: Neurology Date completed: 2015-04-10 Type: Venture financing Raised: $2 million Investors: HRA Pharma; existing investors; angel investors; private investors Note: The financing is a series A-2 round. WIR Staff...
BioCentury | Apr 2, 2012
Clinical News

Embera preclinical data

...significantly reduced the number of self-administered IV nicotine infusions from baseline vs. vehicle-treated controls (p<0.05). Embera...
...to greater reductions in the number of nicotine self-administrations compared to metyrapone or oxazepam alone. Embera...
...2013. Data were published in Psychopharmacology. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Chantix varenicline. Embera NeuroTherapeutics Inc....
BioCentury | Aug 22, 2011
Financial News

Embera financial update

...Ventures co-led the extension. Undisclosed private investors participated. The company raised $1.3 million in 2007. Embera NeuroTherapeutics Inc....
BioCentury | Aug 26, 2010
Distillery Therapeutics

Indication: Neurology

...vigabatrin (CPP-109) and CPP-115 in Phase II and preclinical testing, respectively, to treat cocaine addiction. Embera NeuroTherapeutics Inc.'s...
BioCentury | Feb 22, 2010
Company News

Embera neurology news

...Embera retained Exponential Pharma Ventures LLC to assist in seeking a partner to advance Embera's lead...
...of generic drugs, metyrapone and oxazepam, has completed a pilot trial to treat cocaine addiction. Embera...
...and receive an option for an exclusive, worldwide license to develop and commercialize the compound. Embera NeuroTherapeutics Inc....
BioCentury | Jan 7, 2008
Clinical News

EMB 001: Phase Ib started

...Phase Ib trial to compare oral EMB-001 vs. placebo in 45 patients for 6 weeks. Embera NeuroTherapeutics Inc....
Items per page:
1 - 10 of 12
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...created position, and Michael Detke as CMO. Detke, who succeeds Samer Kaba, was CMO of Embera NeuroTherapeutics Inc....
BioCentury | Aug 15, 2016
Company News

Embera, NIH neurology news

...on Drug Abuse (NIDA) to develop metyrapone/oxazepam ( EMB-001 ) to treat cocaine use disorder. Embera...
...plans to advance the product through a Phase II proof-of-concept trial with the NIDA support. Embera NeuroTherapeutics Inc....
BioCentury | Jan 25, 2016
Clinical News

Metyrapone/oxazepam: Phase I data

...metyrapone/24 mg oxazepam. After 24 hours, subjects received twice-daily doses of EMB-001 for 7 days. Embera NeuroTherapeutics Inc....
BioCentury | Jun 15, 2015
Clinical News

Metyrapone/oxazepam: Phase I started

...metyrapone/24 mg oxazepam. After 24 hours, subjects will then receive twice-daily doses for 7 days. Embera NeuroTherapeutics Inc....
BioCentury | Apr 13, 2015
Financial News

Embera completes venture financing

Embera NeuroTherapeutics Inc. , Shreveport, La. Business: Neurology Date completed: 2015-04-10 Type: Venture financing Raised: $2 million Investors: HRA Pharma; existing investors; angel investors; private investors Note: The financing is a series A-2 round. WIR Staff...
BioCentury | Apr 2, 2012
Clinical News

Embera preclinical data

...significantly reduced the number of self-administered IV nicotine infusions from baseline vs. vehicle-treated controls (p<0.05). Embera...
...to greater reductions in the number of nicotine self-administrations compared to metyrapone or oxazepam alone. Embera...
...2013. Data were published in Psychopharmacology. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Chantix varenicline. Embera NeuroTherapeutics Inc....
BioCentury | Aug 22, 2011
Financial News

Embera financial update

...Ventures co-led the extension. Undisclosed private investors participated. The company raised $1.3 million in 2007. Embera NeuroTherapeutics Inc....
BioCentury | Aug 26, 2010
Distillery Therapeutics

Indication: Neurology

...vigabatrin (CPP-109) and CPP-115 in Phase II and preclinical testing, respectively, to treat cocaine addiction. Embera NeuroTherapeutics Inc.'s...
BioCentury | Feb 22, 2010
Company News

Embera neurology news

...Embera retained Exponential Pharma Ventures LLC to assist in seeking a partner to advance Embera's lead...
...of generic drugs, metyrapone and oxazepam, has completed a pilot trial to treat cocaine addiction. Embera...
...and receive an option for an exclusive, worldwide license to develop and commercialize the compound. Embera NeuroTherapeutics Inc....
BioCentury | Jan 7, 2008
Clinical News

EMB 001: Phase Ib started

...Phase Ib trial to compare oral EMB-001 vs. placebo in 45 patients for 6 weeks. Embera NeuroTherapeutics Inc....
Items per page:
1 - 10 of 12